Novacyt SA Company Top Insiders
NVYTF Stock | USD 0.70 0.13 22.81% |
Novacyt SA employs about 210 people. The company is managed by 7 executives with a total tenure of roughly 490 years, averaging almost 70.0 years of service per executive, having 30.0 employees per reported executive. Examination of Novacyt SA's management performance can provide insight into the company performance.
Steve Gibson Insider Group Controller |
David Franks Insider Chief Officer |
Novacyt |
Novacyt SA Management Team Effectiveness
The company has return on total asset (ROA) of 0.0145 % which means that it generated a profit of $0.0145 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0198) %, meaning that it generated substantial loss on money invested by shareholders. Novacyt SA's management efficiency ratios could be used to measure how well Novacyt SA manages its routine affairs as well as how well it operates its assets and liabilities.Novacyt SA Workforce Comparison
Novacyt SA is considered to be number one stock in number of employees category among its peers. The total workforce of Medical Devices industry is now estimated at about 1,438. Novacyt SA retains roughly 210 in number of employees claiming about 15% of all equities under Medical Devices industry.
The company has Profit Margin (PM) of (0.1) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.07 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.07. Novacyt SA Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Novacyt SA Price Series Summation is a cross summation of Novacyt SA price series and its benchmark/peer.
Novacyt SA Notable Stakeholders
A Novacyt SA stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Novacyt SA often face trade-offs trying to please all of them. Novacyt SA's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Novacyt SA's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Steve Gibson | Group Controller | Profile | |
David Franks | Chief Officer | Profile | |
Grald Ulrich | Chief Devel | Profile | |
James McCarthy | Acting CFO | Profile | |
Bryan Close | Chief Officer | Profile | |
Wendy Karban | Group Mang | Profile | |
Paul Oladimeji | Group RD | Profile |
About Novacyt SA Management Performance
The success or failure of an entity such as Novacyt SA often depends on how effective the management is. Novacyt SA management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Novacyt management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Novacyt management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. The company was incorporated in 2006 and is based in Vlizy-Villacoublay, France. Novacyt operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 210 people.
Novacyt SA Workforce Analysis
Traditionally, organizations such as Novacyt SA use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Novacyt SA within its industry.Novacyt SA Manpower Efficiency
Return on Novacyt SA Manpower
Revenue Per Employee | 456.1K | |
Revenue Per Executive | 13.7M | |
Net Loss Per Employee | 46.3K | |
Net Loss Per Executive | 1.4M |
Complementary Tools for Novacyt Pink Sheet analysis
When running Novacyt SA's price analysis, check to measure Novacyt SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novacyt SA is operating at the current time. Most of Novacyt SA's value examination focuses on studying past and present price action to predict the probability of Novacyt SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novacyt SA's price. Additionally, you may evaluate how the addition of Novacyt SA to your portfolios can decrease your overall portfolio volatility.
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance |